Actelion's macitentan meets primary endpoint in pivotal Phase III SERAPHIN ... 
MarketWatch (press release)
Allschwil, Switzerland, Apr 30, 2012 (Thomson Reuters ONE via COMTEX) -- Actelion Pharmaceuticals Ltd / Actelion's macitentan meets primary endpoint in pivotal Phase III SERAPHIN outcome study in patients with pulmonary arterial hypertension .
Actelion Says Hypertension Drug Macitentan Met Primary Goals In Pivotal Study RTT News
Critical drug trials boost Actelion Financial Times
Actelion surges as positive PhIII macitentan data reignites buyout buzz FierceBiotech
Chicago Tribune  -InPharm 
all 35 news articles » 

Pulmonary Arterial Hypertension - Phase III SERAPHIN Outcome Study Meets ... 
Medical News Today
SERAPHIN (Study with an Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome) was the largest randomized, controlled study in pulmonary arterial hypertension patients with a long-term treatment, ...
Actelion Lung Drug Meets Main Goal in Pivotal Patient Study Bloomberg
Actelion's Macitentan Lung Drug Meets Clinical Study Goal Wall Street Journal
Actelion's macitentan meets primary endpoint in pivotal Phase III PAH study The Pharma Letter
Reuters  -Pharma Times 
all 17 news articles » 

VentriPoint Launches Clinical Trial in Pulmonary Arterial Hypertension (PAH ... 
SYS-CON Media (press release)
"With our successful pilot study completed and the PAH application validated, we are ready to start the clinical trial which will study 75 patients with PAH using both cardiac MRI and the VMS(TM) ultrasound approach," stated Dr. George Adams, ...

and more » 

Actelion presents its strategy for value creation 
Reuters
1) Expanding Actelion's leadership in the PAH market Actelion is well positioned to expand its leadership in the PAH market following the recent successful conclusion of the landmark SERAPHIN morbidity/mortality study with macitentan in patients ...
Actelion sees no earnings growth until 2014 Chicago Tribune
Actelion sees return to growth in 2014 Reuters UK

all 25 news articles » 

Synthetic Biologics Reports First Quarter 2012 Financial Results 
MarketWatch (press release)
Initiated preclinical research for the development of a synthetic DNA-based therapy for pulmonary arterial hypertension (PAH), utilizing the UltraVector® platform and RheoSwitch Therapeutic System® of our collaborator, Intrexon Corporation.
Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of ... Sacramento Bee

all 22 news articles » 

VentriPoint VMS? Heart Analysis System Installed at Allegheny General ... 
Marketwire (press release)
The first Pulmonary Arterial Hypertension (PAH) patient has completed the MRI and VMS? scans. The VMS? heart analysis system works with all existing 2D cardiac ultrasound machines to obtain 3D functional information in 15 minutes.

and more » 

VentriPoint 3D Heart Analysis System Approved for Pulmonary Arterial ... 
Healthcare Global (press release)
VentriPoint Diagnostics Ltd. ("VentriPoint" or the "Corporation") (TSX VENTURE:VPT) (OTCQX:VPTDF) is pleased to announce that it has received approval from Health Canada for VentriPoint's new Pulmonary Arterial Hypertension ("PAH") application for the ...

and more » 

Synthetic Biologics Reports First Quarter 2012 Financial Results 
Sacramento Bee
Initiated preclinical research for the development of a synthetic DNA-based therapy for pulmonary arterial hypertension (PAH), utilizing the UltraVector® platform and RheoSwitch Therapeutic System® of our collaborator, Intrexon Corporation.

and more » 

GlaxoSmithKline: Complied With Indian Rules for Drug Approval 
Wall Street Journal
By RUMMAN AHMED BANGALORE ? GlaxoSmithKline PLC said Thursday it was granted a waiver on conducting clinical trials in India for ambrisentan, its drug to treat pulmonary arterial hypertension, as local rules allow such a concession for drugs treating a ...
GlaxoSmithKline: complied with India rules MarketWatch
GlaxoSmithKline: Complied With Indian Rules In Getting Heart, Lung Drug Approved Fox Business
Drug firms lay onus of medicine approvals at DCGI door-step Hindu Business Line
Wall Street Journal (India) (blog)  -Financial Times 
all 249 news articles » 

VentriPoint Launches Clinical Trial in Pulmonary Arterial Hypertension (PAH ... 
Healthcare Global (press release)
"With our successful pilot study completed and the PAH application validated, we are ready to start the clinical trial which will study 75 patients with PAH using both cardiac MRI and the VMS? ultrasound approach," stated Dr. George Adams, ...